$7,983,650 Contingent Income Auto-Callable Securities Based on the Performance of the Common Stock of Moderna, Inc. due October 04, 2024, priced on October 01, 2021, were issued by Morgan Stanley Finance LLC. The pricing supplement for this note (CUSIP: 61773E734) can be found here. The notes had a $10 face value and paid a quarterly coupon of $0.2525, so long as the notes had not been called and and Moderna all closed above 50% of their October 01, 2021 closing prices on a determination date. If and Moderna closed below 50% of their October 01, 2021 closing prices on a determination date, the notes did not pay a coupon. If not previously called, at maturity, the notes returned $10 in principal if and Moderna all closed on the final determination date on October 01, 2024 and above 50% of their October 01, 2021 closing prices. If on October 01, 2024 and Moderna closed below 50% of their October 01, 2021 closing prices, the notes paid reduced principal euqal to $10 multiplied by the lowest ratio of and Moderna October 01, 2024 closing prices to their October 01, 2021 closing prices. The notes have matured. They paid four coupons totaling $0.7575 and $1.87 repayment per $10 note. Investors thus suffered capital losses of $8.13 and net losses of $7.37.† In the aggregate, investors in this note suffered $6,487,286 in capital losses and $5,882,525 in net losses. See Table 1 and Figure 1.
SLCG Economic Consulting, LLC ("SLCG") provides finance, economics, and investment management consulting services. Our clientele includes law firms, banks, brokerage firms, and individuals embroiled in complex litigation, for whom we offer expert witness services. Our team consists of highly qualified professionals holding PhD and MA-level degrees, with extensive experience across academia, industry, and government. We have provided expert testimony in state and federal courts, and in arbitration forums. SLCG is a wholly owned subsidiary of McCann Yan Holdings, Inc., a Virginia incorporated company based in Northern Virginia.